Ionis holder plans sale of 5,296 shares

Ionis Pharmaceuticals had a Form 144 notice filed for the potential sale of 5,296 shares of its common stock through Morgan Stanley Smith Barney on or about 01/30/2026.

Accepted by SEC EDGAR 01/30/2026 - 08:50 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Ionis Pharmaceuticals had a Form 144 notice filed for the potential sale of 5,296 shares of its common stock through Morgan Stanley Smith Barney on or about 01/30/2026. The filing lists an aggregate market value of $439,693.50 for these shares on Nasdaq.

The shares to be sold were acquired on 01/29/2026 as performance stock units granted under the company’s 2011 Equity Incentive Plan as compensation. The notice states that 161,974,393 shares of common stock were outstanding and discloses a prior sale of 6,907 shares for $523,205.25 on 01/16/2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Ionis Pharmaceuticals (IONS) Form 144 filing disclose?

The Form 144 filing discloses a planned sale of Ionis Pharmaceuticals common stock. It covers 5,296 shares to be sold through Morgan Stanley Smith Barney on or about January 30, 2026, under Rule 144 resale provisions for restricted or control securities.

How many Ionis Pharmaceuticals (IONS) shares are planned to be sold?

The notice covers a proposed sale of 5,296 Ionis Pharmaceuticals common shares. These shares are to be sold on Nasdaq, with Morgan Stanley Smith Barney listed as broker, and are part of a Rule 144 transaction for the person on whose behalf the filing is made.

What is the market value of the Ionis Pharmaceuticals (IONS) shares in this Form 144?

The filing reports an aggregate market value of $439,693.50 for the 5,296 Ionis Pharmaceuticals common shares to be sold. This value reflects the market pricing used in the notice and relates specifically to the proposed Rule 144 sale on or about January 30, 2026.

How were the Ionis Pharmaceuticals (IONS) shares being sold acquired?

The shares were acquired on 01/29/2026 as performance stock units granted under Ionis Pharmaceuticals’ 2011 Equity Incentive Plan. The filing describes the nature of the payment as compensation, indicating these securities were received as part of an equity-based compensation award rather than a cash purchase.

What prior Ionis Pharmaceuticals (IONS) share sales are disclosed in the last 3 months?

The notice lists a prior sale on 01/16/2026 of 6,907 Ionis Pharmaceuticals common shares, with gross proceeds of $523,205.25. Morgan Stanley Smith Barney is again shown as the seller’s broker, providing context on recent selling activity associated with this account.

How many Ionis Pharmaceuticals (IONS) shares were outstanding in this Form 144?

The filing states that 161,974,393 Ionis Pharmaceuticals common shares were outstanding. This figure serves as a baseline share count in the notice and helps contextualize the relative size of the 5,296-share sale covered by the Form 144 filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001813775
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	IONIS PHARMACEUTICALS INC
SEC File Number	000-19125
Address of Issuer	2855 GAZELLE COURT CARLSBAD CALIFORNIA 92010
Phone	7609319200
Name of Person for Whose Account the Securities are To Be Sold	Baroldi Joseph
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney 1585 Broadway New York NY 10036	5296	439693.50	161974393	01/30/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/29/2026	PSU granted under 2011 Equity Incentive Plan	Ionis Pharmaceuticals			5296	01/29/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Morgan Stanley Smith Barney 1585 Broadway New York NY 10036	Common Stock	01/16/2026	6907	523205.25

144: Remarks and Signature

Remarks
Date of Notice	01/30/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Joseph T. Baroldi
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)